Clinical Trials Arena on MSN15h
MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drug
Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda was able to reduce the time patients spent in the chemotherapy chair.
Cure Today10d
FDA Approves Keytruda in HER2+ Gastric, Gastroesophageal Junction Cancer
FDA approved Keytruda with Herceptin and chemotherapy for HER2-positive gastric/GEJ adenocarcinoma with PD-L1 expression. KEYNOTE-811 study showed improved progression-free and overall survival with ...